pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)
Amgen
Amgen is a pharma organization headquartered in Thousand Oaks, USA. Primary therapeutic focus areas include Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorec
Company details
- Status
- Public
- HQ
- One Amgen Center Drive, Thousand Oaks, CA 91320, US
- Founded
- 1980
- Employees
- 40,212
- Programs
- 96
- Drugs
- 124
- Patents
- 25
20170770
Phase 3 · small molecule · Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
20170770 for Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer is a Phase 3 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).
Internal code 20170770
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Amgen
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
- Status
- active
- Trials
- 1